CCL2 antibody (AA 24-96)

Catalog No. ABIN6719598

This anti-CCL2 antibody is a Rabbit Polyclonal antibody detecting CCL2 in WB and ELISA. Suitable for Mouse and Rat.

Quick Overview for CCL2 antibody (AA 24-96) (ABIN6719598)

Target: CCL2 (Chemokine (C-C Motif) Ligand 2 (CCL2))

Reactivity: Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This CCL2 antibody is un-conjugated

Application: Western Blotting (WB), ELISA

Product Details anti-CCL2 Antibody

Binding Specificity: AA 24-96

Purpose: Anti-CCL2 Antibody Picoband®

Cross-Reactivity (Details): No cross-reactivity with other proteins.

Characteristics: Anti-CCL2 Antibody Picoband® (ABIN6719598). Tested in ELISA, WB applications. This antibody reacts with Mouse, Rat. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Purification: Immunogen affinity purified.

Immunogen: E. coli-derived rat CCL2 recombinant protein (Position: Q24-R96).

Isotype: IgG

Application Details

Application Notes: Western blot, 0.1-0.5 μg/mL
ELISA (Cap), 1-5 μg/mL
1. Furutani, Y., Nomura, H., Notake, M., Oyamada, Y., Fukui, T., Yamada, M., Larsen, C. G., Oppenheim, J. J., Matsushima, K. Cloning and sequencing of the cDNA for human monocyte chemotactic and activating factor (MCAF). Biochem. Biophys. 2. Gosling, J., Slaymaker, S., Gu, L., Tseng, S., Zlot, C. H., Young, S. G., Rollins, B. J., Charo, I. F. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Invest. 103: 773-778, 1999. 3. Gu, L., Okaka, Y., Clinton, S. K., Gerard, C., Sukhova, G. K., Libby, P., Rollins, B. J. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low absorbance lipoprotein receptor-deficient mice.

Comment:

Tested Species: In-house tested species with positive results. Other applications have not been tested. Optimal dilutions should be determined by end users.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.

Concentration: 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl and 0.2 mg Na2HPO4.

Storage: 4 °C,-20 °C

Storage Comment: Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles.

Target Details for CCL2

Target: CCL2 (Chemokine (C-C Motif) Ligand 2 (CCL2))

Alternative Name: Ccl2

Background:

Synonyms: C-C motif chemokine 2, Immediate-early serum-responsive protein JE, Monocyte chemoattractant protein 1, Monocyte chemotactic protein 1, MCP-1, Small-inducible cytokine A2, Ccl2, Je, Mcp1, Scya2

Tissue Specificity: Detected in various tissues including thymus, liver, lung, heart, and adult ovary.

Background: Monocyte chemoattractant protein-1 (MCP-1), a member of the chemokine (chemotactic cytokine) family, is a potent monocyte agonist that is upregulated by oxidized lipids. MCP-1 is also known as CCL2, SCYA2, MCAF. MCAF is a member of family of factors involved in immune and inflammatory responses. The amino acid sequence deduced from the nucleotide sequence reveals the primary structure of the MCAF precursor to be composed of a putative signal peptide sequence of 23 amino acid residues and a mature MCAF sequence of 76 amino acid residues. MCP-1 plays a unique and crucial role in the initiation of atherosclerosis and may provide a new therapeutic target in this disorder. Human MCP-1 is a 8.7KDa non-glycoprotein, consisting of 99 amino acids in precursor form and 76 amino acids in mature form.

Molecular Weight: 11 kDa

Gene ID: 24770

UniProt: P14844

Pathways: Cellular Response to Molecule of Bacterial Origin, Positive Regulation of Immune Effector Process, ER-Nucleus Signaling, Unfolded Protein Response, The Global Phosphorylation Landscape of SARS-CoV-2 Infection